These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
49. Effects of urinary macromolecules on the nucleation of calcium oxalate in idiopathic stone formers and healthy controls. Borghi L; Meschi T; Guerra A; Bergamaschi E; Mutti A; Novarini A Clin Chim Acta; 1995 Jul; 239(1):1-11. PubMed ID: 7586581 [TBL] [Abstract][Full Text] [Related]
50. Twenty-Four Hour Urine Testing and Prescriptions for Urinary Stone Disease-Related Medications in Veterans. Song S; Thomas IC; Ganesan C; Sohlberg EM; Chertow GM; Liao JC; Conti S; Elliott CS; Pao AC; Leppert JT Clin J Am Soc Nephrol; 2019 Dec; 14(12):1773-1780. PubMed ID: 31712387 [TBL] [Abstract][Full Text] [Related]
51. Seasonal variation in urinary excretion of calcium, oxalate, magnesium and phosphate on free and standard mineral diet in men with urolithiasis. Juuti M; Heinonen OP; Alhava EM Scand J Urol Nephrol; 1981; 15(2):137-41. PubMed ID: 7330607 [TBL] [Abstract][Full Text] [Related]
52. The effect of allopurinol on urinary oxalate excretion in stone formers. Scott R; Paterson PJ; Mathieson A; Smith M Br J Urol; 1978 Dec; 50(7):455-8. PubMed ID: 753494 [TBL] [Abstract][Full Text] [Related]
53. Use of potassium citrate as potassium supplement during thiazide therapy of calcium nephrolithiasis. Nicar MJ; Peterson R; Pak CY J Urol; 1984 Mar; 131(3):430-3. PubMed ID: 6699979 [TBL] [Abstract][Full Text] [Related]
54. A biochemical basis for grouping of patients with urolithiasis. Tiselius HG; Almgård LE; Larsson L; Sörbo B Eur Urol; 1978; 4(4):241-9. PubMed ID: 668734 [TBL] [Abstract][Full Text] [Related]
55. Is selective therapy of recurrent nephrolithiasis possible? Pak CY; Peters P; Hurt G; Kadesky M; Fine M; Reisman D; Splann F; Caramela C; Freeman A; Britton F; Sakhaee K; Breslau NA Am J Med; 1981 Oct; 71(4):615-22. PubMed ID: 7282750 [TBL] [Abstract][Full Text] [Related]
56. High fluid intake or pharmacological therapy in recurrent stone former patients? Aroldi A; Graziani G; Passerini P; Castelnovo C; Mandressi A; Trinchieri A; Colussi G; Ponticelli C Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():743-6. PubMed ID: 3991571 [TBL] [Abstract][Full Text] [Related]
58. Calcium oxalate stone disease: effects and side effects of cellulose phosphate and succinate in long-term treatment of absorptive hypercalciuria or hyperoxaluria. Hautmann R; Hering FJ; Lutzeyer W J Urol; 1978 Dec; 120(6):712-5. PubMed ID: 731812 [TBL] [Abstract][Full Text] [Related]
59. Acute acid load in recurrent oxalate stone formers. Knispel HH; Fitzner R; Kaiser M; Butz M Urol Int; 1988; 43(2):93-6. PubMed ID: 3388639 [TBL] [Abstract][Full Text] [Related]
60. [14C]Oxalate absorption by normal persons, calcium oxalate stone formers, and patients with surgically disturbed intestinal function. Tiselius HG; Ahlstrand C; Lundström B; Nilsson MA Clin Chem; 1981 Oct; 27(10):1682-5. PubMed ID: 7285319 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]